Patients with metastatic HR+HER2− IBC demonstrated a shorter time on treatment suggesting shorter duration of response on CDKI + HT, which is markedly inferior to reported data for non-IBC patients from phase III trials. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.